Skip to main content
SpringerLink
Log in

Application of pharmacokinetic-pharmacodynamic modelling in management of QT abnormalities after citalopram overdose

  • Original
  • Published:
Intensive Care Medicine Aims and scope Submit manuscript

Abstract

Objective

To develop guidelines for the management of QT prolongation after citalopram overdose, including decontamination with single-dose activated charcoal (SDAC) and cardiac monitoring.

Design

Simulation study using a previously developed pharmacokinetic-pharmacodynamic (PKPD) model which predicted the time-course of QT prolongation and the effect of citalopram dose and use of SDAC on QT prolongation.

Main measures and results

The previously developed PKPD model was used to address the following in patients following citalopram overdose: (1) Above what dose should patients be decontaminated? (2) Above what dose should patients have cardiac monitoring? (3) For what period of time should patients be monitored? The primary outcome was QT,RR combinations above an abnormal threshold as a surrogate predictor of torsades de pointes. Simulations were performed using MATLAB for an overdose patient with typical demographics: 30-year-old female with a heart rate of 79 bpm taking citalopram therapeutically. The simulations showed: (1) There was significant benefit associated with the administration of SDAC to patients following citalopram overdose ingesting > 600 mg; (2) With citalopram overdoses > 1,000 mg it was advisable to give SDAC and cardiac monitor the patient; (3) The risk of developing future abnormal QT,RR combinations was less than 1% in patients with normal QT,RR combinations up to 13 h post-dose, so the minimum monitoring time for citalopram overdoses > 1,000 mg should be 13 h. Recommended dose levels for intervention should be lowered in older patients and patients with tachycardia, while men are less sensitive to QT prolongation.

Conclusions

Guidelines for the management of QT prolongation after citalopram overdose were developed. We believe the model will help clinicians to decide which patients to decontaminate and monitor.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Isbister GK, Bowe SJ, Dawson A, Whyte IM (2004) Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. J Toxicol Clin Toxicol 42:277–285

    Article  PubMed  CAS  Google Scholar 

  2. Personne M, Sjöberg G, Persson H (1997) Citalopram overdose—review of cases treated in Swedish hospitals. J Toxicol Clin Toxicol 35:237–240

    Article  PubMed  CAS  Google Scholar 

  3. Meuleman C, Jourdain P, Bellorini M, Sadeg N, Loiret J, Guillard N, Thebault B, Funck F (2001) [Citalopram and Torsades de Pointes. A case report]. Arch Mal Coeur Vaiss 94:1021–1024

    PubMed  CAS  Google Scholar 

  4. Tarabar AF, Hoffman RS, Nelson LS (2003) Citalopram overdose: Late presentation of Torsades de Pointes (TdP) with cardiac arrest [abstract]. J Toxicol Clin Toxicol 41:676

    Google Scholar 

  5. Ostrom M, Eriksson A, Thorson J, Spigset O (1996) Fatal overdose with citalopram. Lancet 348:339–340

    Article  PubMed  CAS  Google Scholar 

  6. Jonasson B, Saldeen T (2002) Citalopram in fatal poisoning cases. Forensic Sci Int 126:1–6

    Article  PubMed  CAS  Google Scholar 

  7. Chew DP, Allan RM, Aroney CN, Sheerin NJ (2005) National data elements for the clinical management of acute coronary syndromes. Med J Aust 182:S1–14

    PubMed  Google Scholar 

  8. Bond GR (2002) The role of activated charcoal and gastric emptying in gastrointestinal decontamination: a state-of-the-art review. Ann Emerg Med 39:273–286

    Article  PubMed  Google Scholar 

  9. Cooper GM, Le Couteur DG, Richardson D, Buckley NA (2005) A randomized clinical trial of activated charcoal for the routine management of oral drug overdose. QJM 98:655–660

    Article  PubMed  CAS  Google Scholar 

  10. Friberg LE, Isbister GK, Duffull SB (2006) Pharmacokinetic-pharmacodynamic modelling of QT interval prolongation following citalopram overdoses. Br J Clin Pharmacol 61:177–190

    Article  PubMed  CAS  Google Scholar 

  11. Rampono J, Kristensen JH, Hackett LP, Paech M, Kohan R, Ilett KF (2000) Citalopram and demethylcitalopram in human milk; distribution, excretion and effects in breast fed infants. Br J Clin Pharmacol 50:263–268

    Article  PubMed  CAS  Google Scholar 

  12. Friberg LE, Isbister GK, Hackett LP, Duffull SB (2005) The population pharmacokinetics of citalopram after deliberate self-poisoning: a Bayesian approach. J Pharmacokinet Pharmacodyn 32:571–605

    Article  PubMed  CAS  Google Scholar 

  13. Moss AJ (1999) The QT interval and torsade de pointes. Drug Saf 21:1:5–10

    Google Scholar 

  14. Malik M, Farbom P, Batchvarov V, Hnatkova K, Camm AJ (2002) Relation between QT and RR intervals is highly individual among healthy subjects: implications for heart rate correction of the QT interval. Heart 87:220–228

    Article  PubMed  CAS  Google Scholar 

  15. Fossa AA, Wisialowski T, Magnano A, Wolfgang E, Winslow R, Gorczyca W, Crimin K, Raunig DL (2005) Dynamic beat-to-beat modeling of the QT-RR interval relationship: analysis of QT prolongation during alterations of autonomic state versus human ether a-go-go-related gene inhibition. J Pharmacol Exp Ther 312:1–11

    Article  PubMed  CAS  Google Scholar 

  16. Balit CR, Isbister GK, Hackett LP, Whyte IM (2003) Quetiapine poisoning: a case series. Ann Emerg Med 42:751–758

    Article  PubMed  Google Scholar 

  17. Isbister GK, Balit CR (2003) Bupropion overdose: QTc prolongation and its clinical significance. Ann Pharmacother 37:999–1002

    Article  PubMed  Google Scholar 

  18. Batchvarov VN, Ghuran A, Smetana P, Hnatkova K, Harries M, Dilaveris P, Camm AJ, Malik M (2002) QT-RR relationship in healthy subjects exhibits substantial intersubject variability and high intrasubject stability. Am J Physiol Heart Circ Physiol 282:H2356–H2363

    PubMed  CAS  Google Scholar 

  19. Sidhu J, Priskorn M, Poulsen M, Segonzac A, Grollier G, Larsen F (1997) Steady-state pharmacokinetics of the enantiomers of citalopram and its metabolites in humans. Chirality 9:686–692

    Article  PubMed  CAS  Google Scholar 

  20. Kragh-Sorensen P, Overo KF, Petersen OL, Jensen K, Parnas W (1981) The kinetics of citalopram: single and multiple dose studies in man. Acta Pharmacol Toxicol (Copenh) 48:53–60

    CAS  Google Scholar 

  21. Malik M, Hnatkova K, Batchvarov V, Gang Y, Smetana P, Camm AJ (2004) Sample size, power calculations, and their implications for the cost of thorough studies of drug induced QT interval prolongation. Pacing Clin Electrophysiol 27:1659–1669

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

Geoff Isbister is funded by an NHMRC Clinical Career Development Award ID300785. Lena Friberg was supported by a research grant from Knut and Alice Wallenberg foundation, Stockholm, Sweden

Author information

Authors and Affiliations

  1. Tropical Toxinology Unit, Menzies School of Health Research, Charles Darwin University, Darwin, Australia

    Geoffrey K. Isbister

  2. Department of Clinical Toxicology, Newcastle Mater Hospital, Edith St, NSW 2298, Waratah, Australia

    Geoffrey K. Isbister

  3. School of Pharmacy, University of Queensland, Brisbane, Australia

    Lena E. Friberg & Stephen B. Duffull

Authors
  1. Geoffrey K. Isbister
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lena E. Friberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stephen B. Duffull
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Geoffrey K. Isbister.

Additional information

G.K. I. and S.B. D. conceived and, with L.E. F., designed the study. G.K. I. supervised the clinical study and data collection. L.E. F. undertook pharmacokinetic-pharmacodynamic modelling and simulations based on the model, under the supervision of S.B. D.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Cite this article

Isbister, G.K., Friberg, L.E. & Duffull, S.B. Application of pharmacokinetic-pharmacodynamic modelling in management of QT abnormalities after citalopram overdose. Intensive Care Med 32, 1060–1065 (2006). https://doi.org/10.1007/s00134-006-0183-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00134-006-0183-9

Keywords

Search

Navigation